Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2)
- Target
- ARNT2
- Molecular classification
- Transcription factor, bHLH-PAS family protein
01
Overview
Aryl hydrocarbon receptor nuclear translocator 2 is a transcription factor that functions as a molecular partner for sensor proteins from the bHLH-PAS superfamily, forming heterodimers that regulate diverse developmental, environmental, and metabolic responses. ARNT2 is primarily expressed in neural tissues but also shows expression in other organs. It plays key roles in responses to hypoxia (with HIF1α), xenobiotic metabolism (with AhR), and neurogenesis. ARNT2's activity is crucial for gene regulation during development and environmental stress, and its dysregulation has been linked to neoplastic and neurodevelopmental diseases
- Other names
- ARNT2Aryl hydrocarbon receptor nuclear translocator type 2Basic helix-loop-helix PAS transcription factor ARNT2
02
Mechanism of action
Small molecules binding to AhR induce its translocation and heterodimerization with ARNT2, activating transcription of target genes. Drugs modulating hypoxia pathways may affect ARNT2 activity indirectly as part of HIF complexes
03
Biological functions
Heterodimerization with sensor proteins (e.g., AhR, HIF1α, NPAS4)Regulates transcription of genes responsive to developmental and environmental stimuli (such as hypoxia and xenobiotic metabolism)Neurogenesis regulation, especially in the central nervous system
04
Disease associations
Cancer (implicated in tumor biology via interaction partners and hypoxic regulation)Neurodevelopmental disordersOther: acute myeloblastic leukemia (through fusion proteins)
05
Safety considerations
Modulation may affect broad gene networks, including those regulating cell proliferation, survival, and metabolismPotential for off-target effects due to shared bHLH/PAS domain family structureEffects on neurodevelopment and tumorigenesis suggest caution in therapeutic strategies
06
Interacting drugs
No direct drugs targeting ARNT2 are currently approved or widely reported; however, its dimerization partners (AhR, HIF1α) are targeted by drugs or investigational agents. Ligands for AhR (e.g., Tapinarof, FICZ, benzo[a]pyrene, β-naphthoflavone, Indigo, Indirubin) may indirectly affect ARNT2/AhR complexes
07
Biomarkers
No established biomarkers specifically for ARNT2 patient selection; its interaction partners (AhR, HIF1α) are more commonly used as biomarkers (e.g., in cancer/hypoxia studies)
Beyond the preview
Go deeper on Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2).